Abstract
dc:descriptionTechnologies within single-cell omics have revolutionised our ability to explorecellular heterogeneity with remarkable precision. Encompassing a range ofmethods that can analyse the molecular characteristics of individual cells, single-cellomics promise to provide valuable insights into the DNA, RNA, and proteinlevels at a single-cell resolution. In particular, single-cell RNA-sequencing (scRNAseq)and spatial-omics stand out as pivotal tools providing insights into geneexpression profiles, transcriptional states, and the spatial organisation of cancercells, thereby providing leverage to reveal the cellular heterogeneity of cancercells and the tumour microenvironment (TME). Especially in the context of cancermetastasis, which remains a therapeutic enigma, the use of scRNA-seq andspatial-omics can be used to delineate the complex cellular landscapes oftumours and identify the interactions within the TME, providing crucial informationfor developing targeted therapies and improving patient outcomes. In Paper I, we investigate clear cell renal cell carcinoma (ccRCC) using scRNA-seqto analyse primary tumours and their metastatic counterparts. A distincttranscriptional signature was identified in tumour cells that predicts metastaticpotential and patient survival and highlights the role of the TME, particularlyvascular remodelling and an immunosuppressive microenvironment in promotingmetastasis. Finally, we highlight potential therapeutic targets, such as theCXCL9/CXCL10-CXCR3 and CD70-CD27 axes, as potential targets for treatments. In Paper II, building on the insights of Paper I, we use scRNA-seq to analyse theTME of primary and bone metastatic ccRCC with a unique comparison to the tumourinvolved-, benign- and healthy- bone marrow. Our findings highlight a populationof tumour-associated mesenchymal stromal cells promoting epithelial-tomesenchymaltransition and bone remodelling as well as an immunosuppressivemicroenvironment with exhausted CD8+ T cells and tumour-associatedmacrophages that aids the metastatic process to bone. Finally, we show thattumour-associated mesenchymal cells exert their effects on bone remodelling viathe RANK/RANKL/OPG signalling pathway, crucial for regulating bone resorptionand remodelling in metastatic sites and suggest the pathway as a therapeutictarget. In Paper III, we investigated spatially resolved chromosomal aberrations in high-riskneuroblastoma (NB) patient samples and cell lines using spatial omics. Wedescribe the tumour clonal landscape in patient samples and the evolutionarytrajectories of cells in response to chemotherapy in NB cell lines. We reveal thattargeting both proliferation and DNA damage response pathways via acombination treatment with doxorubicin, gemcitabine, and an ATM inhibitor, caneffectively reduce tumour growth and inhibit regrowth both in vitro and in vivo,highlighting the importance of addressing genetic and phenotypic heterogeneityin NB. Overall, this thesis provides novel insights into the intricate cellular landscape ofprimary and metastatic tumours as well as their surrounding microenvironments,revealing potential culprits of the metastatic process. Using high-resolutionsingle-cell omics technologies, we enable the identification of key therapeutictargets and the development of more effective, personalised treatment strategiesto combat cancer metastasis.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsea, Ioanna
- Τσέα, Ιωάννα
Subjects
dc:subject × 10Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60078